Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Change in Accured Expenses (2016)

Historic Change in Accured Expenses for Gsk (GLAXF) over the last 8 years, with Q4 2016 value amounting to -$1.0 billion.

  • Gsk's Change in Accured Expenses fell 34488.81% to -$1.0 billion in Q4 2016 from the same period last year, while for Dec 2016 it was $2.9 billion, marking a year-over-year increase of 5931.72%. This contributed to the annual value of $3.2 billion for FY2018, which is 4065.31% up from last year.
  • Per Gsk's latest filing, its Change in Accured Expenses stood at -$1.0 billion for Q4 2016, which was down 34488.81% from $1.5 billion recorded in Q3 2016.
  • In the past 5 years, Gsk's Change in Accured Expenses ranged from a high of $2.2 billion in Q2 2016 and a low of -$2.5 billion during Q3 2012
  • Its 5-year average for Change in Accured Expenses is $172.8 million, with a median of $340.5 million in 2015.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first skyrocketed by 664405.97% in 2012, then crashed by 34488.81% in 2016.
  • Gsk's Change in Accured Expenses (Quarter) stood at $212.0 million in 2012, then skyrocketed by 200.18% to $636.3 million in 2013, then skyrocketed by 73.8% to $1.1 billion in 2014, then crashed by 62.13% to $418.8 million in 2015, then plummeted by 344.89% to -$1.0 billion in 2016.
  • Its last three reported values are -$1.0 billion in Q4 2016, $1.5 billion for Q3 2016, and $2.2 billion during Q2 2016.